

CONTENTS

Market View: Markets looking to consolidate

Unilever: FY11 numbers lighter than expected

Shell: Q4 earnings miss expectations

IRISH PAPERS TODAY

Sharp fall in under-25s on live register
(The Irish Times)

74 dead in Egyptian football match violent clashes
(The Irish Independent)

Quinn family in court challenge
(The Irish Times)

INTERNATIONAL PAPERS TODAY

Facebook serves notice on \$5bn IPO
(Financial Times)

Deutsche Bank swings to pre-tax loss
(Wall Street Journal)

Glencore and Xstrata close to \$80bn deal
(Financial Times)

Market View

After steady gains over the past three days on the back of US, EU and Chinese data continuing to suggest resilience in global manufacturing, European markets are set to consolidate today and have opened marginally lower. Optimism is growing that the European debt crisis, which is a major threat to growth, is being reduced as central banks continue to flood the system with liquidity. However, the threat is still there as negotiations continue on the Greek debt talks, Portuguese bond yields remain at unsustainable levels and strikes show underlying discontent at austerity measures. The long-awaited resolution to the Greek debt talks are still pending, the most recent holdup being attributed to differences between the IMF and Germany. The former is looking for official creditors to shoulder some losses, while the latter sees no need for official sector involvement and is calling for deeper cuts in the Greek budget. On the company front the two big stories catching the markets' attention this morning are the proposed \$5bn IPO of Facebook, being led by Morgan Stanley, and the fact the Glencore could be near to an agreement with Xstrata on a merger, something that has been touted since the former's IPO last year. The only data point of note today is US initial jobless claims at 13:30, with consensus at 371,000.

Unilever - Buy

Previous Close 2085p

Target 2240p

Unilever the world's second largest consumer goods company released full year numbers this morning which were a touch lighter than market expectations. Group sales came in at €46.4bn v €46.6bn expected while earnings per share was €1.41 v €1.46 expected. The company, which manufactures Dove Skincare and Knorr soups saw an improvement in pricing but this came at the expense of volumes in some areas however Unilever still gained share in many of its key businesses. Company margins also fell by 10bps for the full year, which was at the higher end of market expectations. Emerging markets, where the company generates over half of its revenue continued to outperform delivering underlying sales growth of 11.5%. In its outlook statement, management acknowledged that while the macro environment was likely to remain tough in FY12, it expects profitable volume growth and steady yet sustainable core operating margin improvement for the full year. The company trades on 14.7x forward earnings and yields a dividend of 3.8%.

Royal Dutch Shell - Buy

Previous Close 2268p

Target 2600p

Royal Dutch Shell has released Q4 earnings this morning that missed market expectations. Earnings were reported at \$4.84bn versus consensus of the \$5.10bn. The reason for the miss was a \$278m loss in the company's downstream business. The market was expecting the oil major to turn a modest profit here, however the loss was the result of continued refining margin pressure. The negative impact in the Downstream was offset somewhat by the Upstream which recorded a solid quarter with earnings coming in ahead of expectations at \$5.10bn. Production fell in the quarter to 3305k/boepd however this was ahead of expectations at 3200k/boepd and resulted in the stronger Upstream numbers. As part of the results Royal Dutch Shell stated that it may grow its dividend this year which should see its payout rise from \$0.42 a share to somewhere closer to \$0.45 a share. On the whole the results are disappointing however it was believed that the market had been guided lower into results so the weak quarter had been anticipated. The prospect of an increased dividend is a positive however this afternoon's conference call will be a key driver as the company sets out its new growth agenda. We remain a buyer of the stock with a 2600p price target.

Regulatory Information

Regulatory Information

Dolmen Securities Limited is regulated by the Central Bank of Ireland. Dolmen Securities Limited is a member firm of the London Stock Exchange. Dolmen Stockbrokers is regulated by the Central Bank of Ireland. Dolmen Stockbrokers is a member firm of the Irish Stock Exchange and the London Stock Exchange.

This report has been prepared by Dolmen Stockbrokers ('Dolmen') for information purposes in order to assist investors to make their own investment decisions and is not intended to and does not constitute personal recommendations nor provide the sole basis for any evaluation of the securities discussed. Specifically the information contained in this report should not be taken as an offer or solicitation of investment advice or, encourage the purchase or sale of any particular security, option, future or other derivative investment. Not all recommendations are necessarily suitable for all investors and Dolmen recommend that specific advice should always be sought prior to investment, based on the particular circumstances of the investor.

Although the information in this report has been obtained from sources, which Dolmen believes to be reliable and all reasonable efforts are made to present accurate information Dolmen give no warranty or guarantee as to, and do not accept responsibility for, the correctness, completeness, timeliness or accuracy of the information provided or its transmission. Nor shall Dolmen, or any of its employees, directors or agents, be liable to for any losses, damages, costs, claims, demands or expenses of any kind whatsoever, whether direct or indirect, suffered or incurred in consequence of any use of, or reliance upon, the information. Any person acting on the information contained in this report does so entirely at his or her own risk.

All estimates, views and opinions included in this report constitute Dolmen's judgment as of the date of the report but may be subject to change without notice. Changes to assumptions may have a material impact on any recommendations made herein.

Unless specifically indicated to the contrary this report has not been disclosed to the covered issuer(s) in advance of publication.

Past performance is not a reliable guide to future performance. The value of your investment may go down as well as up. Investments denominated in foreign currencies are subject to fluctuations in exchange rates, which may have an adverse affect on the value of the investments, sale proceeds, and on dividend or interest income. The income you get from your investment may go down as well as up. Figures quoted are estimates only; they are not a reliable guide to the future performance of this investment. Investors should be aware that forwarding looking statements and forecasts may not be realised.

This report is the property of Dolmen and may not be reproduced (in whole or in part) altered, transmitted or made available to any other person without the prior written permission of Dolmen.

Conflicts of Interest & Share Ownership Policy

Unless specifically stated to the contrary in this report, Dolmen, its employees, directors or related companies, do not hold shares in the stocks covered in this report.

It is noted that research analysts' compensation is impacted upon by overall firm profitability and accordingly may be affected to some extent by revenues arising other Dolmen business units including Corporate Finance, Fund Management and Stockbroking. Revenues in these business units may derive in part from the recommendations or views in this report. Notwithstanding, Dolmen is satisfied that the objectivity of views and recommendations contained in this report has not been compromised.

Dolmen permits research analysts to own shares and/ or derivative positions in the companies they publish research, views and recommendations on. Accordingly analysts involved in the production of this report may have positions in any securities herein. Dolmen ensures that all staff dealing is undertaken in strict compliance with Dolmen's internal staff dealing procedures. Therefore Dolmen is satisfied that the impartiality of research, views and recommendations remains assured.

Our conflicts of interest management policy is available at the following link;
http://www.dolmenstockbrokers.ie/regulation_mifld.shtml

Analyst Certification

Each research analyst responsible for the content of this report, in whole or in part, certifies that: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Ian Hunter, Brian Gallagher and John Mullane are responsible for the production of this report. Ian Hunter, Brian Gallagher and John Mullane are equity analysts.

For US Persons Only

This report is only provided in the US to major institutional investors as defined by s.15 a-6 of the Securities Exchange Act, 1934 as amended. A US recipient of this report shall not distribute or provide this report or any part thereof to any other person.

Other important disclosures

A description of Dolmen's basis of valuation or any other methodology used to evaluate a financial instrument or issuer or to set a price target and the meaning of any recommendation made such as buy, sell or hold is set out at:

<http://www.dolmenstockbrokers.ie/disclosures.shtml>

Prices quoted in this report, unless otherwise indicated, are as of close on the previous trading day.

A summary of existing and prior price targets for each company under coverage is available at <http://www.dolmenstockbrokers.ie/disclosures.shtml>

Dolmen Stockbrokers, 75 St. Stephen's Green, Dublin 2, Ireland.



DOLMEN SECURITIES LTD

75 St. Stephen's Green, Dublin 2, Ireland.
45 South Mall, Cork, Ireland
Theatre Court, Mallow St, Limerick, Ireland.

Tel : +353 1 633 3800/1890 400 300
Tel : +353 21 422 2122
Tel : +353 61 436 500

E-mail: info@dsl.ie
E-mail: cork@dsl.ie
E-mail: Limerick@dsl.ie